Chlorpromazine dose for people with schizophrenia

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 4, 2017, Pages

  Dudley, Katharine ^a   Liu, Xiaomeng ^b   De Haan, Saskia ^c  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UTRECHT UNIVERSITY   (Netherlands)

^c GGZ Noord Holland Noord   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; BARBITURIC ACID DERIVATIVE; CHLORAL HYDRATE; HYPNOTIC SEDATIVE AGENT; NEUROLEPTIC AGENT;

ANTICHOLINERGIC SYNDROME; CARDIOVASCULAR DISEASE; CLINICAL OUTCOME; DOSE RESPONSE; ENDOCRINE DISEASE; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; LIVER DISEASE; MENTAL HEALTH; METABOLIC DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SKIN DISEASE; SYSTEMATIC REVIEW; UROGENITAL TRACT DISEASE; DRUG ADMINISTRATION; META ANALYSIS; PATIENT DROPOUT; STATISTICS AND NUMERICAL DATA;

ANTIPSYCHOTIC AGENTS; BARBITURATES; CHLORAL HYDRATE; CHLORPROMAZINE; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPNOTICS AND SEDATIVES; PATIENT DROPOUTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA;

EID: 85018485014     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007778.pub2     Document Type: Review

References (126)

1. Chouinard G, Annable L. Alpha-methyldopa-chlorpromazine combination in schizophrenic patients. Neuropsychobiology 1976;2(2-3):118-26. 3273883
2. Clark M, Dubowski K, Colmore J. The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clinical Pharmacology and Therapeutics 1970;11:883-9. 3273885
3. Clark ML, Ramsey HR, Ragland RE, Rahhal DK, Serafetinides EA, Costiloe JP. Chlorpromazine in chronic schizophrenia - behavioral dose-response relationships. Psychopharmacology [Psychopharmacologia] 1970;18(3):260-70. 3273886
4. Clark ML, Ramsey HR, Rahhal DK, Serafetinides EA, Wood FD, Costiloe JP. Chlorpromazine in chronic schizophrenia. The effect of age and hospitalization on behavioral dose-response relationships. Archives of General Psychiatry 1972;27(4):479-83. 3273887
5. Serafetinides EA, Willis D, Clark ML. EEG dose-response relationships of chlorpromazine in chronic schizophrenia: the effects on the various rhythms and on alpha blocking. Biological Psychiatry 1972;4:251-6. 3273888
6. Ayd FJ. Neuroleptic therapy for chronic schizophrenia. Diseases of the Nervous System 1972;33(1):35-9. [MEDLINE: 5059687]5305642
7. De Long SL. Incidence and significance of chlorpromazine-induced eye changes. Diseases of the Nervous System 1968;29:19-22. 5305643
8. Gardos G, Cole JO, LaBrie RA. A 12 year follow up study of chronic schizophrenics. Hospital and Community Psychiatry 1982;33(12):983-4. 3273890
9. Prien RF, Cole JO. High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health - psychopharmacology research branch collaborative study group. Archives of General Psychiatry 1968;18(4):482-95. 3273892
10. Prien RF, Cole JO, Belkin NF. Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication. British Journal of Psychiatry 1968;115(523):679-86. 3273891
11. Prien RF, DeLong SL, Cole JO, Levine J. Ocular changes occurring with prolonged high dose chlorpromazine therapy. Results from a collaborative study. Archives of General Psychiatry 1970;23(5):464-8. 3273893
12. Prien RF, Levine J, Cole JO. High dose therapy in chronic schizophrenia - trifuoperazine. 121st Annual Meeting of the American Psychiatric Association; 1968 May 13-17; Boston (MA). Boston (MA): American Psychiatric Association, 1968. 5305644
13. Prien RF, Levine J, Cole JO. Indications for high dose chlorpromazine therapy in chronic schizophrenia. Diseases of the Nervous System 1970;31(11):739-45. 3273894
14. Prien RF, Levine J, Switalski RW. Discontinuation of chemotherapy for chronic schizophrenics. Hospital and Community Psychiatry 1971;22(1):4-7. [MEDLINE: 4992967]5305645
15. Wode-Helgodt B, Borg S, Fyro B, Sedvall G. Clinical effects and drug concentrations in plasma and cerebrospinal fluid in psychotic patients treated with fixed doses of chlorpromazine. Acta Psychiatrica Scandinavica 1978;58(2):149-73. 3273896
16. Wode-Helgodt B, Eneroth P, Fyro B, Gullberg B, Sedvall G. Effect of chlorpromazine treatment on prolactin levels in cerebrospinal fluid and plasma of psychotic patients. Acta Psychiatrica Scandinavica 1977;56(4):280-93. 3273897
17. Wode-Helgodt B, Fyro B, Gullberg B, Sedvall G. Effect of chlorpromazine treatment on monoamine metabolite levels in cerebrospinal fluid of psychotic patients. Acta Psychiatrica Scandinavica 1977;56(2):129-42. 3273898
18. Xu Y, Gao H, Li M, Li X. Different doses of clozapine and chlorpromazine in the treatment of schizophrenia clinical research. Archives of Psychiatry 2009;22(3):203-4. 3273900
19. Altman H, Mehta D, Evenson RC, Sletten IW. Behavioral effects of drug therapy on psychogeriatric inpatients: I. chlorpromazine and thioridazine. Journal of the American Geriatrics Society 1973;21(6):241-8. 3273902
20. Andrews P, Hall JN, Snaith RP. A controlled trial of phenothiazine withdrawal in chronic schizophrenic patients. British Journal of Psychiatry 1976;128:451-5. 3273904
21. Bartko G, Sztaniszlav D, Olajos S, Bekesy M. Serum chlorpromazine and prolactin levels in paranoid schizophrenic patients and clinical response. Regional Symposium of the World. European Journal of Psychiatry 1988;2(2):109-17. [PsycINFO]3273906
22. Borison RL, Diamond BI, Dren AT. Does sigma receptor antagonism predict clinical antipsychotic efficacy?. Psychopharmacology Bulletin 1991;27(2):103-6. 3273908
23. Caffey EM, Prien RF. Practical considerations on treatment with antipsychotic preparations. Zhurnal nevropatologii i psikhiatrii imeni s. S. Korsakova 1975;75(9):1399-401. 3273910
24. Casey JF, Hollister LE, Klett CJ, Lasky JJ, Caffey EM. Combined drug therapy of chronic schizophrenics. Controlled evaluation of placebo, dextro-amphetamine, imipramine, isocarboxazid and trifluoperazine added to maintenance doses of chlorpromazine. American Journal of Psychiatry 1961;117:997-1003. 3273912
25. Chen L. A comparative study of EEG changes in patients treated by risperidone, chlorpromazine and clozpine. Journal of Qiqihar Medical College 2002;23(5):485-6. 3273914
26. Clark ML, Johnson PC. Amenorrhea and elevated level of serum cholesterol produced by a trifluoro-methylated phenothiazine (SKF-5354-A). The Endocrine Society April 1960;20:641-6. 3273916
27. Clark ML, Ray TS, Paredes A, Costiloe JP, Chappell JS, Hagans JA, et al. Chlorpromazine in chronic schizophrenic women: I. Experimental design and effects at maximum point of treatment. Psychopharmacologia 1961;2:107-36. 3273918
28. Clark M, Dubowski K, Colmore J. The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clinical Pharmacology and Therapeutics 1970;11:883-9. 3273920
29. Clark ML, Ray TS, Paredes A, Ragland RE, Costiloe JP, Smith CW, et al. Chlorpromazine in women with chronic schizophrenia: the effect on cholesterol levels and cholesterol-behavior relationships. Psychosomatic Medicine 1967;29(6):634-42. [PUBMED: 5582955]3273921
30. Clark M, Dubowski K, Colmore J. The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clinical Pharmacology and Therapeutics 1970;11:883-9. 3273923
31. Clark ML, Kyriakopoiilos A, Ragland RE. Chlorpromazine in chronic schizophrenic women: its effect on thyroid and liver function in relation to serum cholesterol concentration. Pharmacologia Clinica 1970;2(4):227-30. 3273924
32. Clark M, Dubowski K, Colmore J. The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clinical Pharmacology and Therapeutics 1970;11:883-9. 3273926
33. Clark ML, Huber WK, Sakata K, Fowles DC, Serafetinides EA. Molindone in chronic schizophrenia. Clinical Pharmacology and Therapeutics 1970;11(5):680-8. 3273927
34. Clark ML, Kaul PN. A preliminary report on clinical response and blood levels of chlorpromazine and its sulfoxide during chlorpromazine therapy in chronic schizophrenic patients. In: Gottschalk LA, Merlis S editor(s). Pharmacokinetics of Psychoactive Drugs. New York (NY): Spectrum Publications, 1976:191-7. 3273930
35. Clark ML, Kaul PN, Whitfield LR. Chlorpromazine kinetics and clinical response. Psychopharmacology Bulletin 1978;14(3):43-5. 3273929
36. Cooper SF, Albert JM, Hillel J, Caille G. Plasma-level studies of chlorpromazine following the administration of chlorpromazine hydrochloride and chlorpromazine embonate in chronic schizophrenics. Current Therapeutic Research, Clinical and Experimental 1973;15(2):73-7. 3273932
37. Crane GE. Tardive dyskinesia in schizophrenic patients treated with psychotropic drugs. Agressologie 1968;9(2):209-16. [MEDLINE: 5675488; PsycINFO]3273934
38. Curry SH. Antipsychotic drugs. I. chlorpromazine: pharmacokinetics, plasma levels and clinical response. In: Burrows GD, Norman T editor(s). Plasma Levels of Psychotropic Drugs and Clinical Response. New York (NY): Marcel Dekker, 1978. 3273936
39. Curry SH. Metabolism and kinetics of chlorpromazine in relation to effect. In: Sedvall G, Uvnas B, Zotterman Y editor(s). Antipsychotic Drugs: Pharmacodynamics and Pharmacokinetics. Oxford: Pergamon Press, 1976:343-52. 3273937
40. Danion JM, Peretti S, Grange D, Bilik M, Imbs JL, Singer L. Effects of chlorpromazine and lorazepam on explicit memory, repetition priming and cognitive skill learning in healthy volunteers. Psychopharmacology [Psychopharmacologia] 1992;108(3):345-51. 3273939
41. Eitan N, Levin Y, Ben Artzi E, Levy A, Neumann M. Effects of antipsychotic drugs on memory functions of schizophrenic patients. Acta Psychiatrica Scandinavica 1992;85(1):74-6. 3273941
42. Gibbs JJ, Wilkens B, Lauterbach CG. A controlled clinical psychiatric study of chlorpromazine. Journal of Clinical and Experimental Psychopathology 1957;18:269-83. 5305647
43. Gibbs JJ, Wilkens B, Lauterbach CG. A controlled clinical psychiatric study of the drug chlorpromazine. American Journal of Psychiatry 1956; Vol. 113:254-5. 5305648
44. Green JF, King DJ. The effects of chlorpromazine and lorazepam on abnormal antisaccade and no-saccade distractibility. Biological Psychiatry 1998;44:709-15. 3273943
45. Green JF, McElholm A, King DJ. A comparison of the sedative and amnestic effects of chlorpromazine and lorazepam. Psychopharmacology 1996;128:67-73. 3273944
46. Hartley L, Henry T, Couper-Smartt J. Chlorpromazine and serial reaction performance. British Journal of Psychology 1978;69:271-6. 3273946
47. Janakiramaiah N, Channabasavanna SM, Narashimha Murthy NS. ECT-chlorpromazine combination versus chlorpromazine alone in acutely schizophrenic patients. Acta Psychiatrica Scandinavica 1982;66(6):464-70. 3273948
48. Jeste DV, Olgiati SG, Ghali AY. Masking of tardive dyskinesia with four times-a-day administration of chlorpromazine. Diseases of the Nervous System 1977;38(9):755-8. 3273950
49. Joshi VG, Nagesh R, Eswaran S, Nagesh R, Pai M, Matthews G, et al. Vitamins B1, B6, and B12 in the adjunctive treatment of schizophrenia - further studies to examine the effect of reduction of chlorpromazine dosage. Journal of Orthomolecular Psychiatry 1982;11(1):45-9. 3273952
50. Kalyanasundaram S, Shrikhande SA, Machado TA, Kapur RL. Single daily dose chlorpromazine therapy in psychosis. An evaluation. Acta Psychiatrica Scandinavica 1981;64(2):158-66. 3273954
51. Lehmann HE, Wilson WH, Deutsch M. Minimal maintenance medication: effects of three dose schedules on relapse rates and symptoms in chronic schizophrenic outpatients. Comprehensive Psychiatry 1983; Vol. 24, issue 4:293-303. [MEDLINE: 6136389]5305650
52. Ota KY, Kurland AA, Rocha J, Block BA. A comparison of the relative clinical efficacy of two chlorpromazine (CPZ) preparations. Current Therapeutic Research, Clinical and Experimental 1974;16(9):1014-21. 3273956
53. Pigache RM. Effects of placebo, orphenadrine, and rising doses of chlorpromazine, on PAT performance in chronic schizophrenia. A two year longitudinal study. Schizophrenia Research 1993;10(1):51-9. 3273958
54. Schiele B. Comparison of low and high dosage procedures in chlorpromazine therapy. Psychiatric Quarterly 1959;33:252-9. 3273960
55. Sukegawa T, Ito T, Hasegawa M, Mizuno Y, Inagaki A, Sakamoto H, et al. A randomized controlled trial on the dose reduction and simplification for polypharmacy of antipsychotics. Tottori Journal of Clinical Research 2008;1:169-81. 3273962
56. Sukegawa T. Implementation of appropriate administration of antipsychotics - measures to reduce high-dose multiple antipsychotics. Nihon Rinsho 2013;71(4):712-7. 3273964
57. Sukegawa T. Measures to reduce high-dose multiple antipsychotics in Japan. Seishin Shinkeigaku Zasshi 2012;114(6):696-701. 3273965
58. Sukegawa T, Inagaki A, Yamanouchi Y, Inada T, Yoshio T, Yoshimura R, et al. Study protocol: safety correction of high dose antipsychotic polypharmacy in Japan. BMC Psychiatry 2014;14(1):103. 3273967
59. Yuan-Guang C, Guang-Rong X, Jing Ping Z. A study on the relationship between the chlorpromazine plasma levels and clinical response to chlorpromazine administrations in the schizophrenics. Chinese Journal of Neurology and Psychiatry 1994;27(3):153-5. 3273969
60. Adams CE, Bergman H, Irving CB, Lawrie S. Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2013, issue 11. [DOI: 10.1002/14651858.CD003082.pub3; CD003082]
61. Adams CE, Awad G, Rathbone J, Thornley B, Soares-Weiser K. Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD000284.pub3]
62. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200. [OLZ020600]
63. Armitage P. Statistical Methods in Medical Research. Oxford-Edinburgh (UK): Blackwell Scientific Publications, 1971.
64. Barbato A. Schizophrenia and Public Health. Geneva: World Health Organization, 1998. [WHO/MSA/NAM/97.6]
65. Bazire S. Psychotropic Drug Directory 2014. Norwich (UK): Page Bros Ltd, 2014.
66. Bland JM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
67. Joint Fomulary Committee. British National Formulary. 8th Edition. London (UK): BMJ Group and Pharmaceutical Press, 2014.
68. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Aperçu sur la problématique des indices d'efficacité thérapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie 1999;54(4):405-11.
69. Bollini P. Antipsychotic drugs: is more worse? A meta analysis of the published randomised control trials. Psychological Medicine 1994;24:307-16.
70. Carpenter WT Jr, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;330(10):681-90.
71. Clark M, Dubowski K, Colmore J. The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clinical Pharmacology and Therapeutics 1970;11:883-9.
72. David JM. Dose equivalence of the antipsychotic drugs. Journal of Psychiatric Research 1974;11:65-9.
73. de Oliveira Marques L, Soares B, de Lima MS. Trifluoperazine for schizophrenia. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2004, issue 1. [DOI: 10.1002/14651858.CD003545.pub2; CD003545]
74. Deeks J. Issues in the selection for meta-analyses of binary data. 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa. Cape Town, 2000.
75. Deeks JJ, Higgins JPT, Altman DG editor(s). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
76. Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623-9.
77. Dold M, Samara MT, Li C, Tardy M, Leucht S. Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2015, issue 1. [DOI: 10.1002/14651858.CD009831.pub2; CD009831]
78. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
79. Egger M, Davey-Smith G, Schneider M, Minder CSO. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;13:629-34.
80. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
81. Endicott J, Spitzer R, Gleiss J, Cohen CJ. The global assessment scale. A procedure to measuring overall severity of psychiatric disturbance. Archives of General Psychiatry 1976;33:766-71.
82. Essali A, Al-Haj HN, Li C, Rathbone J. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2009, issue 1. [DOI: 10.1002/14651858.CD000059.pub2; CD000059]
83. Fenton M, Rathbone J, Reilly J. Thioridazine for schizophrenia. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2007, issue 3. [DOI: 10.1002/14651858.CD001944.pub2; CD001944]
84. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7-10.
85. Geddes JR, Freemantle N, Harrison P, Bebbington PE. Atypical antipsychotics in the treatment of schizophrenia: a systematic overview and meta-regression analysis. BMJ 2000;321:1371-6.
86. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
87. Guy W. Early Clinical Drug Evaluation (ECDEU) Assessment Manual for Psychopharmacology. Washington, DC: National Institute of Mental Health, 1976:217-22.
88. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
89. Higgins, JPT, Green S, editor(s) . Cochrane Handbook for Systematic Reviews of Interventions. Chichester (UK): John Wiley & Sons, 2008.
90. Higgins JPT, Green S, editor(s) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
91. Higgins JPT, Altman DG, Sterne JAC, editor(s) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
92. Hunter R, Kennedy E, Song F, Gadon L, Irving CB. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2003, issue 2. [DOI: 10.1002/14651858.CD000440; CD000440]
93. Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology 2009;146(1):27-30.
94. Jüni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 2001;323:42-6.
95. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda (NY): Multi-Health Systems, 1986.
96. Koch K, Mansi K, Haynes E, Adams CE, Sampson S, Furtado VA. Trifluoperazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2014, issue 1. [DOI: 10.1002/14651858.CD010226.pub2; CD010226]
97. Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, Hunger H, Kissling W, et al. Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2011, issue 1. [DOI: 10.1002/14651858.CD006626.pub2; CD006626]
98. Kumar A, Strech D. Zuclopenthixol dihydrochloride for schizophrenia. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2005, issue 4. [DOI: 10.1002/14651858.CD005474; CD005474]
99. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003;361:1581-9.
100. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2-3):231-8. [PUBMED: 15982856]
101. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187:366-71. [PUBMED: 16199797]
102. Leucht C, Kitzmantel M, Kane J, Leucht S, Chua WL. Haloperidol versus chlorpromazine for schizophrenia. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2008, issue 1. [DOI: 10.1002/14651858.CD004278.pub2; CD004278]
103. Lipka LJ, Lathers CM, Roberts J. Does chlorpromazine produce cardiac arrhythmia via the central nervous system?. Journal of Clinical Pharmacology 1988;28(11):968-83.
104. Magalhães Pedro VS, Dean O, Andreazza AC, Berk M, Kapczinski F. Antioxidant treatments for schizophrenia. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2016, issue 2. [DOI: 10.1002/14651858.CD008919.pub2; CD008919]
105. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
106. Statistics on Mental Health. Factsheet. Mental Health Foundation 2014.
107. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962;10:799-812.
108. Prien RF, DeLong SL, Cole JO, Levine J. Ocular changes occurring with prolonged high dose chlorpromazine therapy. Results from a collaborative study. Archives of General Psychiatry 1970;23(5):464-8. [MEDLINE: 5478574; MEDLINE: 71030994]3273893
109. Rummel-Kluge C, Kissling W, Leucht S. Antidepressants for the negative symptoms of schizophrenia. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2006, issue 3. [DOI: 10.1002/14651858.CD005581.pub2; CD005581]
110. Saha KB, Bo L, Zhao S, Xia J, Sampson S, Zaman RU. Chlorpromazine versus atypical antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2016, issue 4. [DOI: 10.1002/14651858.CD010631.pub2; CD010631]
111. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359-83.
112. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
113. Seeman P. Atypical antipsychotics: mechanism of action. Canadian Journal of Psychiatry 2002;47(1):27-38.
114. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavacia 1970;212:11-9.
115. Sterne JAC, Egger M, Moher D, editor(s) . Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
116. Tardy M, Huhn M, Kissling W, Engel RR, Leucht S. Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2014, issue 7. [DOI: 10.1002/14651858.CD009268.pub2; CD009268]
117. Tardy M, Dold M, Engel RR, Leucht S. Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2014, issue 7. [DOI: 10.1002/14651858.CD009396.pub2; CD009396]
118. Turner T. Chlorpromazine: unlocking psychosis. BMJ 2007;334(Suppl 1):s7. [PUBMED: 17204765]
119. Tuunainen A, Wahlbeck K. Newer atypical antipsychotic medication versus clozapine for schizophrenia. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2000, issue 2. [DOI: 10.1002/14651858.CD000966; CD000966]
120. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1-75.
121. Weinberger DR, Egan MF, Bertolino A, Callicott JH, Mattay VS, Lipska BK, et al. Prefrontal neurons and the genetics of schizophrenia. Biological Psychiatry 2001;50(11):825-44.
122. Weinberger DR, Harrison PJ. Schizophrenia. 3rd Edition. Chichester (UK): Wiley-Blackwell, 2011.
123. World Health Organisation. The World Health Report 2001 Mental Health: New Understanding, New Hope. www.who.int/whr/2001/en/ (accessed 20 January 2017).
124. World Health Organisation. WHO Model List of Essential Medicines. apps.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf?ua=1. 18th (April 2013) (accessed 20 January 2017).
125. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.
126. Liu X, De Haan S. Chlorpromazine dose for people with schizophrenia. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD007778]